GlassScriptPhysician profile
Nader N Tobia
NPI 1831175447
$10,572.12
in general payments reported to CMS, 2019-2025
49 companies · $1,307 in 2025
The $1,307 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,493 · 2020: $879 · 2021: $1,726 · 2022: $1,576 · 2023: $1,946 · 2024: $1,646 · 2025: $1,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,893 · Education: $5.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,893.36 |
| Education | $5.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,864.27 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,303.01 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,255.88 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $967.07 | 2019-2024 | Xarelto, Spravato |
| Abbvie INC. | $619.06 | 2019-2025 | Linzess, Viberzi, Ubrelvy |
| Pfizer INC. | $548.28 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $482.59 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $446.02 | 2020-2025 | Verquvo, Steglatro |
| Novo Nordisk INC | $385.30 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amarin Pharma, INC. | $279.32 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $251.17 | 2021-2025 | |
| Astellas Pharma US INC | $239.09 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.65 | 2019-2024 | Jardiance |
| Sumitomo Pharma America, INC. | $194.09 | 2023-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $182.66 | 2019-2025 | Rexulti |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nader Tobia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.